Literature DB >> 9114595

Expression of GATA transcription factors in myelogenous and lymphoblastic leukemia cells.

N Minegishi1, S Morita, M Minegishi, S Tsuchiya, T Konno, N Hayashi, M Yamamoto.   

Abstract

In the hematopoietic lineage, the transcription factors GATA-1 and GATA-2 show restricted and largely overlapping expression profiles, but GATA-2 is uniquely expressed in early hematopoietic progenitors. GATA-3 is found exclusively in T cells of hematopoietic lineage. To clarify whether these expression profiles are preserved or changed during the development of malignancies, we analyzed the expression of GATA factors in the blasts from leukemic children. A total of 18 myelogenous leukemia and 24 lymphoblastic leukemia (ALL) cases were investigated. In the majority of the former cases, GATA-2 mRNA expression and the expression of CD34 and c-kit antigens on leukemic cells were demonstrated. In contrast, GATA-2 mRNA and c-kit antigen could not be detected in CD34-positive cells from ALL patients. GATA-3 mRNA was expressed in all T-ALL cases, but not in any precursor B-ALL. These findings suggest that down-regulation of GATA-2 and expression of GATA-3 are important events for the commitment of cells to lymphoid and T cell lineage, respectively. The expression profiles of GATA factors in leukemic cells are generally consistent with those in their normal counterparts, and thus provide a useful tool to determine the lineage commitment of unclassified leukemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114595     DOI: 10.1016/s0925-5710(96)00553-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

1.  Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein.

Authors:  S Tsuzuki; M Towatari; H Saito; T Enver
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Leukemogenesis caused by incapacitated GATA-1 function.

Authors:  Ritsuko Shimizu; Takashi Kuroha; Osamu Ohneda; Xiaoqing Pan; Kinuko Ohneda; Satoru Takahashi; Sjaak Philipsen; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 3.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

Review 4.  Leukemogenesis of the EVI1/MEL1 gene family.

Authors:  Kazuhiro Morishita
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

5.  Single-cell epigenomic variability reveals functional cancer heterogeneity.

Authors:  Ulrike M Litzenburger; Jason D Buenrostro; Beijing Wu; Ying Shen; Nathan C Sheffield; Arwa Kathiria; William J Greenleaf; Howard Y Chang
Journal:  Genome Biol       Date:  2017-01-24       Impact factor: 13.583

6.  Does GATA3 act in tissue-specific pathways? A meta-analysis-based approach.

Authors:  Brian J Wilson
Journal:  J Carcinog       Date:  2008

7.  Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma.

Authors:  Yi-Wei Li; Jia-Xing Wang; Xin Yin; Shuang-Jian Qiu; Han Wu; Rui Liao; Yong Yi; Yong-Sheng Xiao; Jian Zhou; Bo-Heng Zhang; Jia Fan
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

8.  Predicting tissue specific transcription factor binding sites.

Authors:  Shan Zhong; Xin He; Ziv Bar-Joseph
Journal:  BMC Genomics       Date:  2013-11-15       Impact factor: 3.969

9.  Single-cell transcriptional analysis of normal, aberrant, and malignant hematopoiesis in zebrafish.

Authors:  Finola E Moore; Elaine G Garcia; Riadh Lobbardi; Esha Jain; Qin Tang; John C Moore; Mauricio Cortes; Aleksey Molodtsov; Melissa Kasheta; Christina C Luo; Amaris J Garcia; Ravi Mylvaganam; Jeffrey A Yoder; Jessica S Blackburn; Ruslan I Sadreyev; Craig J Ceol; Trista E North; David M Langenau
Journal:  J Exp Med       Date:  2016-05-02       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.